Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

M1755220

Methylprednisolone hydrogen succinate for performance test

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Methylprednisolone hemisuccinate, 11β,17,21-Trihydroxy-6α-methylpregna-1,4-diene-3,20-dione 21-succinate, Methylprednisolone hydrogen succinate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C26H34O8
Numéro CAS:
2921-57-5
Poids moléculaire :
474.54
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

methylprednisolone

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C26H34O8.Na/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24;/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31);/q;+1/p-1/t14-,16-,17-,19-,23+,24-,25-,26-;/m0./s1

Clé InChI

FQISKWAFAHGMGT-SGJOWKDISA-M

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Methylprednisolone hydrogen succinate for performance test EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1435003

6α-Methylprednisolone, United States Pharmacopeia (USP) Reference Standard

1437009

Methylprednisolone hemisuccinate, United States Pharmacopeia (USP) Reference Standard

M1750000

6α-Methylprednisolone, European Pharmacopoeia (EP) Reference Standard

M1755200

Methylprednisolone hydrogen succinate, European Pharmacopoeia (EP) Reference Standard

M1755000

Methylprednisolone acetate, European Pharmacopoeia (EP) Reference Standard

1436006

Methylprednisolone acetate, United States Pharmacopeia (USP) Reference Standard

PHR1718

Methylprednisolone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1717

6α-Methylprednisolone, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001759

Methylprednisolone hydrogen succinate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001736

Methylprednisolone acetate for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001760

Methylprednisolone acetate for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001799

6α-Methylprednisolone, European Pharmacopoeia (EP) Reference Standard

1435036

Methylprednisolone Related Compound C, United States Pharmacopeia (USP) Reference Standard

1435014

Methylprednisolone Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP248

6α-Methylprednisolone, British Pharmacopoeia (BP) Reference Standard

BP249

Methylprednisolone acetate, British Pharmacopoeia (BP) Reference Standard

BP572

Deltamedrane, British Pharmacopoeia (BP) Reference Standard

1437042

Methyl Prednisolone Hemisuccinate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1437020

Methylprednisolone Hemisuccinate Related Compound B, United States Pharmacopeia (USP) Reference Standard

PHR3043

Methylprednisolone Related Compound C, pharmaceutical secondary standard, certified reference material

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H360FD,H373

Classification des risques

Repr. 1B - STOT RE 2

Organes cibles

Adrenal gland,Immune system

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Hirofumi Oyama et al.
Neurologia medico-chirurgica, 52(10), 769-773 (2012-10-26)
A 51-year-old female with a history of rheumatoid arthritis rapidly developed anterior neck pain and paresis in the left upper and lower extremities and right lower extremity, sensory disturbance in the left upper and lower extremities, and bladder and rectal
Christos Krogias et al.
JAMA neurology, 70(8), 1056-1059 (2013-06-20)
A patient with a Caspr2 autoantibodies-associated syndrome had an unusual clinical triad and an excellent response to B-cell-anergizing therapy using the humanized monoclonal antibody tocilizumab directed against the interleukin 6 (IL-6) receptor. A 55-year-old man had an atypical clinical triad
S Pescina et al.
International journal of pharmaceutics, 451(1-2), 12-17 (2013-05-01)
Trans-scleral iontophoresis, i.e. the application of small electric current to enhance drug transport across sclera is an option for non-invasive delivery of corticosteroids to the posterior segment of the eye. In this paper, in vitro trans-scleral iontophoresis of methylprednisolone hemisuccinate
Claudia Druschel et al.
Spine, 38(11), E669-E677 (2013-03-01)
Written mail-out survey. To determine current practice in high-dose methylprednisolone succinate (MPSS) administration for treatment of acute spinal cord injury (SCI) in Germany. Reanalysis of the National Acute Spinal Cord Injury Studies (NASCIS) resulted in criticism of the use of
Lasse Murtomäki et al.
Journal of pharmaceutical sciences, 102(7), 2264-2272 (2013-05-15)
The affinity of a drug to a biological membrane can affect the distribution and the availability of the active compound to its target. Adsorption is usually determined with in vitro distribution studies based on partitioning of the drug between buffer
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique